Nanocrine joins Strategic Ventures Family

The latest addition to SV’s portfolio of impactful engagements, NanocrineTM is a biotech company that provides a next-generation platform for life sciences research and discovery. With its patented Plasmonic Chip technology, Nanocrine pioneers a new era in breakthrough medicine by visualizing real-time live cell signaling.

Nanocrine’s innovative approach has far-reaching implications across diverse fields including neurodegenerative disease, stem cell renewal and differentiation, cardiovascular disease, viral pathogenesis, and cancer metastasis.

Visit their website at https://www.nanocrine.com/ or reach out to Mitchell Hauser to learn more about Nanocrine’s game-changing approach.